Bus drivers twice as likely to be hospitalized for severe COVID-19

Bus drivers were at double the risk of being hospitalized for severe COVID-19 in the later stages of the pandemic, and several occupations in education and healthcare were also at risk of serious illness. This has been shown by a study at the University of Gothenburg.

Novartis reportedly in talks to buy MorphoSys; Astellas cuts PhII program; Silence’s $120M private placement

Plus, news about Adverum, BridgeBio Pharma, Vaxcyte, Corbus and Immunocore: Novartis reportedly in deal talks with MorphoSys: The Swiss Big Pharma is in advanced talks

February 6, 2024

Allogeneic Stem Cell Therapy Falls Short on Stroke Outcomes

Bone marrow-derived allogeneic stem cell therapy shortly after ischemic stroke did not improve outcomes at 90 days, a phase II/III randomized clinical trial known as

January 18, 2024

Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares. – Biotech Investments

Spexis AG / Key word(s): Temporary Suspension 04-Jun-2024 / 20:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.